In addition, our data show that HER2 amplification may be a useful marker in identifying TP53 germline carriers, as six of the seven breast tumors (86%) in TP53 germline mutation carriers had amplification of ERBB2 (HER2). Here, ERBB2 is linked to breast neoplasm.